This project examines the neutralizing antibody responses in the acute/early phases of HIV-1 infection. The ultimate goal is to determine if neutralizing antibodies play a role in virus clearance or reduction in virus load. Based on a limited number of studies, current evidence suggests neutralizing antibodies arise too late to contribute to these early processes. We will take advantage of the Trinidad cohort to examine these questions in more detail. The results will be compared to cellular effector mechanisms and other humoral reactivities proposed for study in other sections of the program. The project will also work closely with 9002 in the isolation and preparation of cloned virus isolates and chimeric virus clones. More specifically we will follow the development of antibody responses which neutralize autologous virus isolates derived from PBMCs as well as heterologous primary and prototypic virus isolates. We will concentrate these efforts on virus and sera obtained in the earliest phases of infection and also continue the analysis through the first several years post sero-conversion. We will also examine other aspects of the humoral immune response including antibody binding to envelope components that may represent targets of neutralizing antibody as well as antibodies that block binding of virus to CD4. In those cases in which autologous neutralization is apparent we will define serologic and/or virologic determinants involved. There remain serious questions about the validity of assays currently utilized to detect neutralization of primary isolates. Rules that govern neutralization of laboratory adapted virus isolates do not apply to primary isolates which seriously impacts on the interpretation of the results that will be obtained in this project. Therefore, an important component of our studies will be developmental efforts aimed at a better understanding of experimental variables that affect antibody neutralization. These will address the artificially activated PBMCs required for growth of most primary isolates and the genomic complexity of the virus preparations.

Project Start
2000-09-01
Project End
2002-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$320,540
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Shen, Xiaoying; Parks, Robert J; Montefiori, David C et al. (2009) In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 83:3617-25
Tomaras, Georgia D; Yates, Nicole L; Liu, Pinghuang et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82:12449-63
Alam, S Munir; Scearce, Richard M; Parks, Robert J et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82:115-25
Montefiori, David C; Altfeld, Marcus; Lee, Paul K et al. (2003) Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 170:3906-14
Montefiori, D C; Hill, T S; Vo, H T et al. (2001) Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75:10200-7
Tokunaga, K; Greenberg, M L; Morse, M A et al. (2001) Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 75:6776-85
Ortiz, G M; Wellons, M; Brancato, J et al. (2001) Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98:13288-93
Tomaras, G D; Greenberg, M L (2001) CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. Front Biosci 6:D575-98
Demarest, J F; Jack, N; Cleghorn, F R et al. (2001) Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 17:1333-44
Tomaras, G D; Lacey, S F; McDanal, C B et al. (2000) CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc Natl Acad Sci U S A 97:3503-8

Showing the most recent 10 out of 12 publications